Physician profile
Blake Geschke
NPI 1710422696
$8,468.55
in general payments reported to CMS, 2019-2025
30 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $2,438 · 2023: $2,431 · 2024: $2,670 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395 · Education: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,394.64 |
| Education | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,375.08 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Optinose US, INC. | $719.27 | 2021-2025 | |
| Genzyme Corporation | $716.09 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $656.14 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $647.58 | 2021-2024 | Hyqvia, Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $587.83 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $456.18 | 2023-2025 | Tezspire |
| Csl Behring | $321.58 | 2022-2025 | Hizentra, Haegarda, Kcentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.18 | 2021-2023 | Spiriva Respimat |
| Alk-Abello, INC | $261.94 | 2021-2025 | Odactra, Grastek, Ragwitek |
| Pharming Healthcare, INC. | $205.64 | 2021-2025 | Ruconest |
| Pfizer INC. | $187.55 | 2022-2024 | |
| Leo Pharma INC. | $165.00 | 2022-2023 | Adbry |
| Kaleo, INC. | $113.14 | 2022-2023 | Auvi-Q |
| Abbvie INC. | $94.68 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.76 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $84.14 | 2022-2024 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $83.08 | 2022-2023 | Airduo Digihaler |
| Blueprint Medicines Corporation | $75.55 | 2023-2024 | Ayvakit |
| Dermavant Sciences, INC. | $50.87 | 2024 | Vtama |
| Incyte Corporation | $50.71 | 2024 | Opzelura |
| Hospira, INC. | $41.89 | 2024 | |
| Aimmune Therapeutics, INC. | $35.55 | 2022 | |
| Genentech USA, INC. | $34.32 | 2023-2024 | Xolair |
| Hikma Pharmaceuticals USA | $29.48 | 2024 | Ryaltris |
| Grifols USA, LLC | $27.73 | 2022 | |
| Lilly USA, LLC | $23.66 | 2024 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $22.47 | 2025 | Neffy |
| Organon LLC | $19.62 | 2025 | Vtama |
| Covis Pharma Gmbh | $16.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Geschke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.